Urinary androgens and breast cancer risk: Results from a long-term prospective study based in Guernsey

British Journal of Cancer

Volumn 82, Issue 9, 2000, Pages 1577-1584

  Wang, D Y ^a   Allen, D S ^b   De Stavola, B L ^c   Fentiman, I S ^c   Brussen, J ^c   Bulbrook, R D ^b   Thomas, B S ^b   Hayward, J L ^b   Reed, M J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Adrenal androgens; Aetiocholanolone; Androsterone; Breast cancer risk; Menopause

Indexed keywords

ANDROGEN; ANDROSTERONE; ETIOCHOLANOLONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METABOLITE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STEROID EXCRETION; STEROID URINE LEVEL; UNITED KINGDOM;

AGE FACTORS; ANDROGENS; BREAST NEOPLASMS; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GREAT BRITAIN; HUMANS; MENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034078466     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Aalen O (1978) Non-parametric inference for a family of counting processes. Ann Stat 6: 701-726
2. Adami HO, Johansson ED, Vegelius J and Victor A (1979) Serum concentration of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer in age-matched controls. Upsala J Med Sci 84: 259-274
3. Adams JB (1983) Hermaphrodiol: a 'new' estrogen and its role in the etiology of human breast cancer. In: Commentaries on Research in Breast Diseases Bulbrook RD, Taylor DJ (eds), pp. 131-161. Alan R. Liss: New York
4. Adams JB (1998) Adrenal androgens and human breast cancer: a new appraisal. Breast Cancer Res Treat 51: 183-188
5. Bonney RC, Scanlon MJ, Reed MJ, Jones DL, Beranek PA and James VHT (1984) Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism. J Steroid Biochem 20: 501-504
6. Bulbrook RD and Hayward JL (1967) Abnormal urinary steroid excretion and subsequent breast cancer. A prospective study in the Island of Guernsey. Lancet i: 519-522
7. Bulbrook RD, Hayward JL and Spicer CC (1971) Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet ii: 395-398
8. Clayton B and Mills M (1993) Statistical Models in Epidemiology. Oxford University Press: Oxford
9. De Waard F (1969) The epidemiology of breast cancer: review and prospects. Int J Cancer 40: 577-586
10. De Waard F, deLaive JWJ and Baanders van Halewjin EA (1960) On bimodal age distribution of mammary carcinoma. Br J Cancer 14: 437-448
11. De Waard F, Baanders van Halewjin EA and Huizinga J (1964) The bimodal age distribution of patients with mammary carcinoma. Cancer 17: 141-151
12. Dorgan JF, Longcope C. Stephenson HE, Falk RT, Miller R and Sciajno R (1996) Relation of prediagnoseic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prevent 5: 533-539
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 13712-13788
14. Grattarola R, Secreto G, Recchione C and Castellini W (1974) Androgens in breast cancer II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet 118: 173-178
15. Hayward JL, Greenwood FC, Glober G, Stemmerman G, Bulbrook RD, Wang DY and Kumaoka S (1978) Endocrine status in normal British. Japanese and Hawaiian-Japanese women. Eur J Cancer 14: 1221-1228
16. Hill P, Garbaczewski L and Kasumi F (1985) Plasma testosterone and breast cancer. Eur J Cancer Clin Oncol 21: 1265-1266
17. Hsieh C-C, Trichopoulos D, Katsouyanni K and Yuasa S (1990) Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 46: 796-800
18. Huggins C, Jensen CV and Cleveland AS (1954) Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectotmized rat. J Exp Med 100: 225-240
19. Kellie AE and Wade AP (1957) The analysis of urinary 17-oxosteroids by gradient elution. Biochem J 66: 196-206
20. Key TJA and Pike MC (1988) The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24: 29-43
21. Key TJA, Wang DY, Brown JB, Allen DS, Moore JW, Bulbrook RD, Fentiman IS and Pike MC (1996) A prospective study of oestrogen excretion and breast cancer risk. Br J Cancer 73: 1615-1619
22. Lynch HT and Lynch JF (1986) Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet 23: 369-372
23. Manton KG and Stallard E (1980) A two-disease model of female breast cancer: mortality in 1969 among white females in the United States. J Natl Cancer Inst 64: 9-16
24. McFadyen IJ, Forrest AP, Prescott RJ, Golder MP, Groom GV, Fahmy DR and Griffiths K (1976) Circulating hormone concentrations in women with breast cancer. Lancet i: 1100-1102
25. Powles T, Eeles R, Ashley S, Eastern D, Chang J. Dowsett M, Tidy A, Viggers J and Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98-101
26. Reed MJ (1995) The discriminant-function test: a marker of Th1/Th2 cell cytokine secretion and breast tumour oestrogen synthesis. Mol Med Today 1: 98-103
27. Salber EJ, Trichopoulos D and MacMahon B (1969) Lactation and reproductive histories of breast cancer patients in Boston, 1965-66. J Natl Cancer Inst 43: 1013-1024
28. Secreto G and Zumoff B (1994) Abnormal production of androgens in women with breast cancer. Anticancer Res 14: 2113-2118
29. Secreto G, Recchione C, Cavalleri A, Miraglia M and Dali V (1993) Circulating levels of testosterone, 17-beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer 47: 269-275
30. Secreto G, Toniolo P, Berrino F, Recchione C, Cavalleri A, Pisani P, Totis A, Fariselli G and Di Pietro S (1991) Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res 51: 2572-2576
31. Seymour-Munn K and Adams JB (1983) Estrogenic effects of 5-androsterone-3β-17β-diol and its possible implication in the etiology of breast cancer. Endocrinology 112: 486-491
32. Thomas BS and Bulbrook RD (1966) Routine assay of urinary dehydroepiandrosterone, androsterone, and aetiocholanolone in urine by gasliquid chromatography. In: Vermeulen A (ed.), Androgens in Normal and Pathological Conditions, pp. 49-53. Excerpta Medica Foundation: Amsterdam
33. Thomas BS and Walton DRM (1968) Chloromethyldimethylsilyl ethers in the routine assay of urinary 11-deoxy-17-oxosteroids by gas-liquid chromatography. J Endocr 41: 203-211
34. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS and Wang DY (1997a) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 75: 1075-1079
35. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS and Wang DY (1997b) A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 76: 401-405
36. Thomas HV, Reeves GK and Key TJ (1997c) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 8: 922-928
37. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P and Pasternack BS (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190-197
38. van Doorn LG, Poortman J, Thijssen JHH and Schwarz F (1981) Action and interactions of 5-androstene-3β,17β-diol and estradiol-17β in the immature rat uterus. Endocrinology 108: 1587-1593
39. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C. Rotmensz N and Boyle P (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352: 93-97
40. Wang DY, Moore JW, Thomas BS, Bulbrook RD, Hayward JL, Abe O, Utsunomiye J, Kumaoka S, Greenwood FC, Glober G and Stemmerman G (1979) Plasma and urinary androgens in women with varying degrees of risk of breast cancer. Eur J Cancer 15: 1269-1274
41. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL and Millis RR (1992) Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 21: 214-221
42. Wang DY, De Stavola BL, Allen DS, Fentiman IS, Hayward JL and Bulbrook RD (1997) Breast cancer risk is positively associated with height. Breast Cancer Res Treat 43: 123-128
43. Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JMG, Koenig KL, Shore RE and Kim MY (1997) Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 145: 1030-1038
44. Zhang Y, Kiel DP, Kreger BF, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D and Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336: 611-617